

the Ophthalmologist

Upfront

Dry eye prevalence
in the US

14

In My View

Refractive surgery for
myopic children

16 – 17

Profession

Questioning the system of
performance payments

40 – 43

Sitting Down With

L V Prasad Eye Institute
Founder, Gullapalli Rao

50 – 51

Keeping up with Precision Medicine

How one team are driving a targeted
onslaught against ocular cancers

20 – 29




Better Sub-Incisional Access Through Advanced Engineering

Meet **Allegro sp**TM

Single Use Silicone I/A

Unique geometry and distal irrigation ports help surgeons remove sub-incisional cortex with precision and ease.



Capsule Friendly¹

Complete silicone coverage and polished ports protect the capsule during I/A and polishing.

Eliminate Reprocessing Concerns

Disposable, pre-assembled design eliminates the risks of improper reprocessing.

Better Visibility

Transparent sleeve provides crystal clear view for greater precision and control.

Firm Response


Benefits of silicone safety with a firm substructure allowing for easy IOL rotation and management of nuclear fragments.



Patent Pending 1. Data on file of comparative cadaver eye testing study done at University of Utah/Moran Eye Institute (0 out of 10 posterior capsule breaks with Allegro, 4 of 10 with a metal I/A tip.)

MicroSurgical Technology (MST) | 8415 154th Ave NE | Redmond, WA 98052
425.861.4002 | 1.888.279.3323 | info@microsurgical.com | www.microsurgical.com

Image of the Month




Chaotic Confetti Cornea


This light-sheet microscopy image depicts a K14CreER^{T2}-Confetti mouse cornea that received a severe epithelial debridement wound, spanning limbus-limbus to mimic limbal stem cell deficiency. In this instance, instead of a neat linear array of multi-colored spokes which typically develop in a normal cornea, a chaotic patchwork evolved eight weeks after injury. The image of the normal confetti cornea can be viewed at: top.txp.to/issues/0916/207.

Image courtesy of Nick Di Girolamo and Mijeong Park, University of New South Wales, Sydney, Australia.

Do you have an image you'd like to see featured in *The Ophthalmologist*?
Contact mark.hillen@texerepublishing.com.



44



32

In My View

- 16 **Deepinder Dhaliwal** cuts through the controversy and makes the case for performing refractive surgery in certain myopic children.
- 17 **Judy Kim** talks about adaptive optics imaging technology; how it's furthering our understanding of retinal disease and how it's managed, and shares her team's latest research findings.
- 19 When it comes to the future of small and solo practices, **Ravi Goel** says: don't believe the hype that mergers and acquisitions are on the horizon. He explains why.

03 Image of the Month

- 09 **Editorial**
Access All Areas,
by Mark Hillen.

On The Cover



Artistic representation of precision medicine: targeting therapies to specific mutations.

Upfront

- 10 Pumping up the Pressure
- 11 Conjunctival Cavalry
- 12 Sweet Revelation
- 13 Releasing the Gene Genie
- 14 Defining Dry Eye
- 15 This Month in Business

Features

- 20 **Keeping up With Precision Medicine**
Ophthalmology leads the way with many revolutionary treatments and technologies... but is trailing behind in the field of oncology. **Rajesh Rao** and his team are looking to change this; he tells us how they're helping patients with ocular cancers access therapies targeted to their disease.

Automate



SPEED & ACCURACY



TRS 5100
Product/Model name:
REFRACTOR RT-5100

The **TRS-5100** automated refraction system represents a powerful technology upgrade from your standard old manual refractor. The sleek, modernized digital system is controlled with a programmable keypad; allowing the doctor to remain comfortably seated throughout the entire exam eliminates repetitive stress injuries. The TRS offers a split prism Jackson Cross cylinder with simultaneous target comparisons, for faster, more accurate and more positive exam experiences. Maximize exam efficiency, patient flow, and overall practice revenue.

- Digital accuracy without error
- Instant comparison of old/new Rx
- Portable control pad
- Multiple automated programs
- Reduces repetitive stress injury
- Large LCD touch screen
- Reverse-tilt screen for patients
- Enhanced patient understanding
- Fully integrated and EMR ready
- Rapid ROI generation

The Difference is Marco.




Designed and Manufactured by NIDEK • Represented by Marco
800-874-5274 • marco.com



HUMANITY IN
SCIENCE AWARD

the
Analytical Scientist



In partnership with

KNAUER



2016 Winner
Waseem Asghar

The
Nominations have
now closed for the
2017 Humanity in
Science Award

**What
is the
Winning
Project for
2017?**

Recognizing Altruism and Innovation

The Humanity in Science Award recognizes and rewards a scientific project that has the potential to make the world a better place.

More information:

www.humanityinscienceaward.com



humanityinscienceaward.com



info@theanalyticalscientist.com



[@humanityaward](https://twitter.com/humanityaward)



[humanityinscienceaward](https://www.facebook.com/humanityinscienceaward)



[humanityinscience](https://www.youtube.com/humanityinscience)

Editor - Mark Hillen
mark.hillen@texerepublishing.com
Associate Editor - Ruth Steer
ruth.steer@texerepublishing.com
Associate Editor - Nick Miller
nick.miller@texerepublishing.com
Content Director - Rich Whitworth
rich.whitworth@texerepublishing.com

Editorial Director - Fedra Pavlou
fedra.pavlou@texerepublishing.com
Publishing Director - Neil Hanley
neil.hanley@texerepublishing.com

Sales Manager - Abigail Mackrill
abigail.mackrill@texerepublishing.com
VP Sales North America - Scott Schmidt
scott.schmidt@texerepublishing.com

Head of Design - Marc Bird
marc.bird@texerepublishing.com

Junior Designer - Hannah Ennis
hannah.ennis@texerepublishing.com

Digital Team Lead - David Roberts
david.roberts@texerepublishing.com

Digital Producer Web/Email - Peter Bartley
peter.bartley@texerepublishing.com

Digital Producer Web/App - Abigail Bradley
abigail.bradley@texerepublishing.com

Audience Insight Manager - Tracey Nicholls
tracey.nicholls@texerepublishing.com

Audience Project Associate - Nina Duffissey
nina.duffissey@texerepublishing.com

Traffic and Audience Associate - Lindsey Vickers
lindsey.vickers@texerepublishing.com

Traffic Manager - Jody Fryett
jody.fryett@texerepublishing.com

Social Media / Analytics Associate - Ben Holah
ben.holah@texerepublishing.com

Events Manager - Alice Daniels-Wright
alice.danielswright@texerepublishing.com

Marketing Manager - Katy Pearson
katy.pearson@texerepublishing.com

Financial Controller - Phil Dale
phil.dale@texerepublishing.com

Accounts Assistant - Kerri Benson
kerri.benson@texerepublishing.com

Chief Executive Officer - Andy Davies
andy.davies@texerepublishing.com

Chief Operating Officer - Tracey Peers
tracey.peers@texerepublishing.com

Change of address
nina.duffissey@texerepublishing.com
Nina Duffissey, The Ophthalmologist,
Texere Publishing Ltd, Haig House, Haig Road,
Knutsford, Cheshire, WA16 8DX, UK

General enquiries
www.texerepublishing.com
info@texerepublishing.com
+44 (0) 1565 745 200
sales@texerepublishing.com

Distribution
The Ophthalmologist (ISSN 2051-4093)
and The Ophthalmologist North America
(ISSN 2398-9270), is published monthly by
Texere Publishing Ltd and is distributed in the
US by UKP Worldwide, 3390 Rand Road,
South Plainfield, NJ 07080
Periodicals postage paid at South Plainfield, NJ
POSTMASTER: Send US address changes
to (Title), (Publisher) C/O 3390 Rand Road,
South Plainfield NJ 07080.

Single copy sales £15/\$20 (plus postage,
cost available on request tracey.nicholls@
texerepublishing.com)
Annual subscription for non-qualified
recipients £110/\$140

Reprints & Permissions - tracey.nicholls@texerepublishing.com
The opinions presented within this publication are those of the authors
and do not reflect the opinions of The Ophthalmologist or its publishers,
Texere Publishing. Authors are required to disclose any relevant financial
arrangements, which are presented at the end of each article, where relevant.
© 2017 Texere Publishing Limited. All rights reserved.
Reproduction in whole or in parts is prohibited.



10

32

50

NextGen

32 First Glimpses of Foveal Function

Can a new understanding of foveal function inform future therapeutic strategies for treating visual disorders? Raunak Sinha shares his research work and findings.

35 Benchmarking Retinal Detachment

We mined PubMed for retinal detachment publications to characterize the trends in the field, and define its most active contributors.


Profession

40 Questioning the System

Frederick Fraunfelder and Stevan Whitt overview the current reimbursement regulatory landscape, discuss what the changes might mean for physicians, and offer practical solutions to potential pitfalls.

44 The Extraocular Muscles in ALS: A Research Riddle

Eye movements and blinking are typically preserved in ALS patients. But why? And how can the answer be translated into a better prognosis?



Sitting Down With

50 Gullapalli Rao, Founder and Chair of the L V Prasad Eye Institute, Hyderabad, India.

OCuSOFT®

retaine® MGD

**Superior Coverage
for Complete Dry
Eye Relief**



**Improves
Tear Film
Stability**



**Decreases
Ocular
Discomfort**



**Reduces
Ocular Surface
Staining**



For more information and to order,
call (800) 233-5469 or visit www.ocusoft.com

**Fourth Generation Tear
Film Enhancement**



I love the big ophthalmology meetings. For me, it's a case of an ever-expanding circle of friends composed of ophthalmologists, scientists, congress staff, fellow journalists, PR and industry types (some of whom are generous with their significant expense accounts...). It's fantastic to see familiar faces and resume conversations against a backdrop of the latest and greatest in ophthalmology. But here's the thing: I think I prefer – and learn more from – the smaller meetings. And I'm not talking about the frustrations people feel when there are two must-see parallel sessions.

I find that the smaller the meeting, the easier it is to access the speakers. Few people reading this editorial will have a “PRESS” ribbon under their ARVO Congress badge, or MEDIA written at the bottom of their AAO pass. (Both of which literally open doors for me.) But even then, I often find it hard to catch the superstar speaker after she or he has presented their latest work on the podium at the bigger conferences. The speaker often gets crowded and has to rush off to another pressing commitment. However, when I found myself at the CXL Experts Meeting in Zurich last year, it was no problem getting hold of the likes of Theo Seiler after he'd presented some impressive data – he was sitting next to me at the back of the room before and after his presentation! I kept bumping into him during coffee and lunch – and he may have been sick of the sight of me by the end of the meeting. In fact, there was a whole host of excellent speakers – top names in the field – and I was able to chat to all of them at some point without issue.

Clearly, these people are busy and in high demand, so that sort of access – and the amount of time you can spend – is rare. And it's something I have to give Robert Osher great credit for. My first visit to his meeting – Cataract Surgery: Telling It Like It Is – was back in January this year. It's by no means small, but the faculty are only there on the condition that they're available to the delegates throughout the (very long) day. I could speak to surgeons like it was a conference a tenth of the size. And that's important. I always have questions and receiving answers makes me better at my job. I'm pretty certain that it's also the same for you. So consider the smaller meetings: if you manage to corner an expert, you might learn more than you could ever imagine...

Mark Hillen
Editor

Upfront

Reporting on the innovations in medicine and surgery, the research policies and personalities that shape the practice of ophthalmology.

We welcome suggestions on anything that's impactful on ophthalmology; please email edit@theophthalmologist.com

Pumping up the Pressure

Can lifting weights raise IOP?

Those who regularly “pump iron” down the gym will be familiar with the physical feelings that come with intense resistance exercise. But what impact may strength exercises have on the body, and IOP in particular? A team from the University of Granada, Spain, found that IOP significantly increased when resistance training exercises were performed (1).

Jesús Vera, lead author of the study, explains what led them to design the project: “We have a really active collaboration with the Faculty of Sport Sciences at the University of Granada, and we have each shown the importance of considering physiological changes induced by anaerobic exercise. This led us to consider changes in IOP.”

Enrolling 17 male military officers from the Spanish Army, the team got them to perform jump squats and bench presses with progressively heavier loads, and measured IOP before and after each load using a rebound tonometer. IOP increase was found to be linearly associated with increasing load, and the bench press was found to induce a greater increase than jump squats at the same relative load. Though they were expecting to see an increase in IOP, Vera says that they “did not expect

the almost perfect linear association between the magnitude of resistance and the change in IOP.” The team also found that five minutes of rest was sufficient time for IOP to return to baseline values.

So what impact do the findings mean for glaucoma management? Vera urges caution: “Recent studies have shown that exercise is beneficial in the management of glaucoma, but our findings were obtained with healthy participants, and therefore the effect on patients with glaucoma still needs to be studied. We also want to highlight that the type and intensity of exercise is of vital importance depending on the main goal of this exercise prescription.”

The team are now focusing on how fitness level impacts IOP increase during different exercise protocols, as well as testing the long-term effects of different physical training programs on baseline IOP levels and IOP responses to exercise. For now, Vera offers some advice: “From this study, and some others that we have recently conducted, we can state that exercise is highly beneficial, but that progressive involvement is desirable; individuals in poorer physical condition manifest higher IOP peaks with exercise and should avoid highly demanding physical activities.” *RS*

Reference

1. J Vera et al., “The acute effect of strength exercises at different intensities on intraocular pressure”, *Graefes Arch Clin Exp, Epub ahead of print* (2017). PMID: 28702697.

Conjunctival Cavalry

Team finds a commensal bacterium in the eye that helps protect the ocular surface from pathogens

The question of whether or not the ocular surface harbors resident microbiota has been under debate for a long time; microbial organisms can be found on the surface of the eye, but they could have arrived there from the surrounding environment. Now there's an answer to this long standing deliberation; a resident ocular biome does exist – and it helps defend the ocular surface from pathogens by tuning local immunity.

“Originally, we were collaboratively studying Muckle-Wells disease, a condition which results in generalized inflammatory syndrome and is accompanied by conjunctivitis, in mice,” says Rachel Caspi, of the National Eye Institute and lead author on the corresponding paper (1). Interested in the conjunctivitis aspect, the team hypothesized that these individuals (and the mice carrying the mutation) may be responding abnormally to normal stimuli from the environment. Caspi says, “We’d also observed that immunologically deficient mice at our facility developed conjunctivitis as they aged. Microorganisms were one possibility so we started to examine healthy and mutant mice, and the rest is history...”

The team identified that *Corynebacterium mastiditis* – a known skin commensal – formed stable colonies on the conjunctiva of wild-type mice bred at their institute, as well as mice provided by a collaborator at Washington University (Figure 1); *C. mastiditis* was not found on the ocular surface of commercially sourced mice.




Figure 1. *C. mastiditis* on the surface of the eye. Frozen sections of whole eyes (with eyelids) were stained with fluorescent probes against *Corynebacterium* spp. Image credit: Rachel Caspi and Anthony St. Leger.

Caspi comments, “We expected to find stimuli from the microbial world on the ocular surface, but didn’t expect them to be ‘permanent’ residents on the eye.”

But how did they demonstrate the bacteria were resident and not simply being reinoculated into the eye from the air, mouth, nose or skin? “It is very difficult to show this, but we were lucky that the mice purchased from commercial vendors lacked this bacterium, and that it could not be transferred through co-housing with mice harboring the bacteria,” explains Caspi. True commensalism was demonstrated through detecting *C. mastiditis* on vendor mice conjunctiva for as long as five weeks after inoculation. “This gives us a measure of confidence that *C. mastiditis* cultured from the eyes of vendor mice had taken up residence and wasn’t the result of continuous reinoculation.”

Interestingly, the team found that the conjunctival commensal helped protect the eye from infection: it induced secretion of interleukin-17 from $\gamma\delta$ T cells, which consequently drove

neutrophil recruitment and secretion of antimicrobial agents into the tears. They also discovered that mice treated with gentamicin and vendor mice lacking *C. mastiditis* showed increased susceptibility to fungal (*Candida albicans*) and bacterial (*Pseudomonas aeruginosa*) infections, respectively.

The team believe their findings have implications for the use of antibiotics to treat conjunctivitis, which Caspi thinks may bring more harm than good. This suggests that current antibiotics should be used for the shortest period possible. Looking to the future, Caspi says, “Probiotics based on bacterial extracts could be developed for the eye to stimulate natural immunity on the ocular surface and promote the body’s own defenses, reducing the need for antibiotics.” RS

Reference

1. AJ St Leger et al., “An ocular commensal protects against corneal infection by driving an interleukin-17 response from mucosal $\gamma\delta$ T cells”, *Immunity*, 47, 148–158 (2017). PMID: 28709803.

Sweet Revelation

Team find that a sugar-modifying enzyme drives pathogenesis in HSV keratitis

Once someone is infected with herpes simplex virus (HSV), they have it for life. But whilst persistent oral infection means recurrent bothersome and painful cold sores, persistent infection of corneal epithelium can cause keratitis – and the symptoms can persevere even when the episode of viral infection has cleared. How and why HSV-1-induced inflammation continues to plague the cornea once infection subsides has so far been somewhat of a mystery... until now.

Enter a team from the University of Illinois at Chicago, USA, who have shown that heparanase, an extracellular enzyme that breaks down the glycosaminoglycan heparan sulfate (HS), drives the pathogenesis of HSV-1 corneal infection (1) (Figure 1). Their key findings?

- In mice with corneal HSV-1 infection, overexpression of heparanase worsened herpetic disease, delayed wound healing, and disrupted cytokine production.
- Heparanase translocated to the nucleus upon infection, driving expression of pro-inflammatory factors and activation of NF-κB.
- Inhibition of enzyme activity decreased viral spread.

Investigators Alek Agelidis and Deepak Shukla tell us more...

What lead to your research?

For many years we have focused on HSV infection, particularly in the eye because herpetic stromal keratitis is a major unresolved medical mystery. It has been known for some time that HS – a glycosaminoglycan important




Figure 1. Summary of findings from the corresponding study. Adapted from (1).

for corneal tissue organization – serves as a major initial attachment site for ocular HSV-1 and many other viral and bacterial pathogens. As heparanase is the only mammalian enzyme capable of breaking down HS, we investigated whether it could be involved in HSV infection of the eye. We previously showed that HSV-1 infection increased heparanase expression in corneal cells, and that the enzyme was required for effective viral release from these cells (2). We also found that overexpressing active heparanase in the cornea dramatically exacerbated keratitis symptoms in mice. This formed the basis for our recent paper which describes multiple mechanisms by which the active enzyme drives some hallmark features of epithelial and stromal keratitis (1).

Did you find what you expected?

We were amazed that heparanase played such important roles in driving inflammation and other symptoms (e.g. neovascularization) in the eye, and were particularly surprised by its involvement in transcriptional regulation of pro-

inflammatory factors that are already known to control chronic eye conditions including keratitis. As heparanase is normally found in the extracellular matrix (ECM), very little is known about its role in cell nuclei.

Does HSV-1 affect just HS?

Although there have been reports that other ECM components are involved in the process of viral entry and may be modulated during infection, their interactions with HSV-1 are unclear. We have focused mainly on heparanase because HS and its associated proteoglycans are major attachment receptors for several pathogens. Since our original discovery in 2015, several other groups have replicated similar findings with other viruses, and we are excited that heparanase appears to have a universal role in infection.

What impact do you foresee from your work?

With our findings, we have advanced the concept of a host-encoded virulence factor – a cellular protein that normally maintains homeostasis but can send


several cellular pathways spiraling out of control when upregulated and activated by a virus. Our work points to important roles for heparanase in corneal inflammation and hopefully will draw additional attention to innate or resident molecules driving inflammation and ocular disease. As we've shown that

inhibiting heparanase reduces corneal symptoms, we hope that a new line of therapy could soon emerge for better management of HSV keratitis. A therapy such as this could have unique dual benefits, stopping viral release and spread as well as reducing inflammation and neovascularization.

Releasing the Gene Genie

The gene therapy era in ophthalmology edges nearer and is making RP... treatable

The last four months have seen a number of landmarks in retinal gene therapy for retinitis pigmentosa (RP). In April, Robert MacLaren performed the first ever human subretinal injection of AAV-XLRPGR gene therapy. But last month, the first phase III clinical trial data were published of Spark Therapeutics' voretigene neparvovec (AAV2-hRPE65v2), as a potential one-time gene therapy candidate for the treatment of patients with vision loss (20/60 or worse) due to confirmed biallelic RPE65-mediated inherited retinal disease (1). In one week in November 2013, 31 individuals were enrolled with 21 being randomized to receive bilateral subretinal voretigene neparvovec injections, and 10 to receive control injections – although one patient from each group withdrew before the injections occurred.



Just like with retinal prostheses, one of the big questions that has to be answered when people perform clinical trials of gene therapies for retinal degenerative diseases like RP is: how do you measure improvement in (or deterioration of) visual outcomes? The Snellen chart isn't particularly informative here. Instead, the investigators chose the change in multi-luminance mobility testing (MLMT) as the trial's primary endpoint. MLMT is a visual assessment that integrates aspects of visual acuity testing, visual field testing and light sensitivity into a quantifiable measure (2). How? With an assault course – or rather, trial participants were instructed to follow arrows on the MLMT course, while avoiding obstacles in or adjacent to the path, traversing raised steps, and identifying a door at the end of the course. Several light levels (ranging from 1–400 lux) were evaluated in order to determine the lowest light level at which participants could successfully navigate the course.

So how did the participants fare? After one year, mean bilateral MLMT score changes were 1.8 (SD 1.1) in the intervention group, and 0.2 (SD 1.0) in the control group (a 1.6 unit difference, 95% CI 0.72–2.41, $p=0.0013$). As a practical

References

1. AM Agelidis et al., "Viral activation of heparanase drives pathogenesis of herpes simplex virus-1", *Cell Rep*, 20, 439–450 (2017). PMID: 28700944.
2. SR Hadigal et al., "Heparanase is a host enzyme required for herpes simplex virus-1 release from cells", *Nat Commun*, 6, 6985 (2015). PMID: 25912399.

measure, 13 of the 20 participants who received the gene therapy managed to complete the MLMT course at the lowest luminance level tested (1 lux), whereas not one of the control group managed to achieve this. Significant improvements, relative to control, were seen in full-field light sensitivity threshold testing ($p=0.0004$), and visual field area with Goldmann III4a stimulus testing ($p=0.0059$) too, although the change in visual acuity averaged over both eyes was not ($p=0.17$). Hearteningly, no therapy-related serious adverse events were observed, and perhaps thanks to the perioperative immunomodulatory regimen employed, "no deleterious immune responses occurred."

The study authors succinctly (and modestly) summarized their work with, "Voretigene neparvovec gene replacement improved functional vision in RPE65-mediated inherited retinal dystrophy previously medically untreatable." The era of gene therapy for retinal disease outside of the clinical trial setting looks like it's got a whole lot closer. *MH*

References

1. S Russell et al., "Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial", *Lancet*, Epub ahead of print (2017). PMID: 28712537.
2. DC Chung et al., "Novel mobility test to assess functional vision in patients with inherited retinal dystrophies", *Clin Exp Ophthalmol*. Epub ahead of print (2017). PMID: 28697537.

Defining Dry Eye

How many US adults have diagnosed dry eye disease, and who is most at risk?

Awareness of (and interest in) dry eye disease (DED) has been on the rise over recent years – and is showing no signs of slowing down. But how many people actually have it and to what degree? A recent study (1) has



provided some answers...

In a bid to provide current estimates on the prevalence of DED among adults (over 18 years of age) in the US, a collaborative team of researchers analyzed 75,000 survey respondents from the National Health and Wellness Survey (NHWS). Participants were asked whether they had ever experienced dry eye, and “Yes” responders were then asked a series of questions on diagnosis, severity and symptoms. Analyzing the data, the team calculated overall

prevalence of diagnosed DED, and using census data for 2013, estimated its prevalence among US adults and demographic populations. The key findings are summarized in the infographic below. *RS*

Reference

1. KF Farrand et al., “Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older”, *Am J Ophthalmol*, Epub ahead of print (2017). PMID: 2870566





This Month in Business

Acquisitions, funding rounds, approvals and IP this month

- Alcon posted its Q2 2017 financial report. During this period, net sales were \$1.5 billion (vision care and surgical sales rose by 2 and 3 percent, respectively), and the company made an operating loss of \$19 million during that time. Parent company, Novartis, reported a net income over the same period of \$2 billion (a rise of \$0.2 billion over Q2 2016's value), with net sales of \$12.2 billion, and an operating income of \$2.3 billion.
- Allegro Ophthalmics announced the completion of a private round of equity financing of \$10.7 million to help progress the clinical evaluation of its lead compound Luminate (ALG-1001) through Phase II and III trials of the drug in patients with diabetic macular edema or vitreomacular traction.
- Lantech has received investments from two investment funds, Visionary Venture Fund and the Global Health Investment Fund, for the further research, development, and commercialization of their nitinol microfilament-based lens fragmentation technology, miLOOP.
- Kala Pharmaceuticals announced that it had priced its initial public offering of 6 million shares of common stock at a price of \$15.00 per share, or aggregate gross proceeds of approximately \$90 million before underwriting discounts, commissions and estimated offering expenses.
- Hot on the heels of its recent acquisition of Malosa Medical, Beaver-Visitec International announced it has acquired the Dutch ophthalmic technology company Vitreq.
- Spark Therapeutics has received two pieces of good news from the FDA regarding Luxturna (voretigene neparvovec – see page 13). The FDA offices of Orphan Products Development and Pediatric Therapeutics have designated it as a drug for a rare pediatric disease, and the company's application for a biologics license for the product was also recently accepted.
- Alimera Sciences have been given approval by the UK's Medicines and Healthcare Products Regulatory Agency to reduce the size of their post-marketing study of Iluvien. Originally intended to follow 800 patients over 5 years, the company states that their study "has shown consistent positive safety data, leading the company to seek a smaller sample size." To date, 550 patients have been enrolled.
- The FDA rejects Ocular Therapeutix' Dextenza for the second time, citing unresolved problems with manufacturing and quality control testing.
- Despite Verily, Samsung and Sony all filing patent applications that pertain to video cameras and intraocular lenses, it's Strathspey Crown LLC that have received the first US patent issued for this combination of technologies, the company announced.

In My View

In this opinion section, experts from across the world share a single strongly-held view or key idea.

Submissions are welcome. Articles should be short, focused, personal and passionate, and may deal with any aspect of ophthalmology. They can be up to 600 words in length and written in the first person.

Contact the editor at edit@theophthalmologist.com

A New Hope

Why certain myopic children should have refractive surgery



By Deepinder K. Dhaliwal, Professor of Ophthalmology at the University of Pittsburgh School of Medicine, PA, USA

Amblyopia therapy might work well for the majority of patients, but there are cases where all conventional options have been tried – and little hope of achieving visual improvements exists. It is in these children that I think there is a role for refractive surgery, and there is some evidence supporting this approach.

Compiled results of PRK and LASIK in patients aged 2–19 years with anisometropic amblyopia are favorable overall in over 200 eyes, with typical gains in best-corrected visual acuity (BCVA) and ~50 percent improvement in binocular fusion and stereopsis observed, with minimal complications (1–7). Favorable visual results have also been achieved in children with bilateral high ametropia, with observed improvements in developmental functions such as communication and socialization (8, 9).

From our pediatric LASIK study, I have seen the benefits of performing refractive surgery in these children firsthand (10). A clear advantage is full-time correction – these patients no longer need contact lenses or spectacles. There are also subjective benefits; we heard from parents that children had increased self-esteem and were happy to no longer need unbalanced myopic

spectacles with one very thick lens. One child even said that they could, for the first time, see the stars.

Of course, there are considerations when performing refractive surgery in children. Because anesthetic gases can interfere with excimer laser function (10), patients need to be induced in a separate room or using a laryngeal mask airway to stop gas escaping. There is also the issue of fixation – children under general anesthesia cannot fixate and forceps are needed to keep the iris plane perpendicular to the laser beam. And of course there are risks. High myopia LASIK can lead to ectasia and there are theoretical flap-related issues (although none were seen in our study); with PRK there is worry about haze and regression, and the use of MMC in children can be risky. Children also need steroid drops after PRK surgery, and there can be issues with compliance.

“One child even said that they could, for the first time, see the stars.”

Another option for these children are phakic IOLs, which have multiple advantages including reversibility, exchangeability, high visual quality, lack of regression and no risk of ectasia or haze. Posterior chamber phakic IOLs have shown significant improvements in VA and binocular function over five years with no reported complications, but whilst anterior chamber iris-fixated IOLs have shown

promising visual results, complications (including accelerated endothelial cell loss, IOL dislocation and pigment dispersion) have been reported (9, 11–16). Some groups have also discussed pediatric refractive lensectomy (\pm IOL), but this has shown mixed results in two studies (33 eyes), and has inherent problems of increased risk of retinal detachment and loss of accommodation (17, 18).

To conclude, it is my view that pediatric refractive surgery should be considered in the myopic amblyopic child if conventional therapy has failed and there is no other option, on the provision that proper guidelines are followed, there is great effort to continue amblyopia therapy post-operatively, and ocular health is maintained in the long-term. It is also my view that pediatric refractive surgery is not indicated if the post-operative risks outweigh the benefits, if long-term follow up has not been studied adequately and preliminary data is raising concerns, or

if the overall health of the eye might be compromised for short-term benefit. The idea of pediatric refractive surgery might be controversial to some, but we need to offer these children in whom conventional therapies are failing some hope of improvement.

Dhaliwal reports the following disclosures: Consultant for Bausch & Lomb; Grant Support from Novabay and Kala Pharmaceuticals.

References

1. EA Paysse et al., *Ophthalmology*, 113, 169–176 (2006). PMID: 16360207.
2. P Nucci, AV Drack. *J AAPOS*, 5, 348–351 (2001). PMID: 11753253.
3. R Autrata et al., *Ophthalmologica*, 219, 72–79 (2005). PMID: 15802930.
4. M O'Keefe, L Nolan. *Br J Ophthalmol*, 88, 19–21 (2004). PMID: 14693763.
5. CB Phillips et al., *J Cataract Refract Surg*, 30, 2522–2528 (2004). PMID: 15617919.
6. L Tychsen et al., *J AAPOS*, 9, 224–233 (2005). PMID: 15956941.
7. WF Astle et al., *J Cataract Refract Surg*, 33, 2028–2034 (2007). PMID: 18053899.
8. EA Paysse et al., *J AAPOS*, 16, 291–297 (2012). PMID: 22681949.
9. L Tychsen et al., *J AAPOS*, 12, 282–289 (2008). PMID: 18589386.
10. DR Cook et al., *Anesth Analg*, 92, 1444–1445 (2001). PMID: 11375823.
11. KK Assil et al., *J Cataract Refract Surg*, 33, 1985–1986 (2007). PMID: 17964411.
12. R Saxena et al., *Ophthalmol*, 115, 608–613. PMID: 17686520.
13. A Pirouzian et al., *Ophthalmol*, 114, 194–19 (2007). PMID: 17198856.
14. EM Chipont et al., *J Refract Surg*, 17, 460–462 (2001). PMID: 11472004.
15. A Ryan et al., *Acta Ophthalmol*, 90, e458–62 (2012). PMID: 22394414.
16. JL Alió et al., *J Refract Surg*, 27, 494–501 (2011). PMID: 21323241.
17. A Ali et al., *J AAPOS*, 11, 153–158 (2007). PMID: 17140827.
18. L Tychsen et al., *J AAPOS*, 10, 357–363 (2006). PMID: 16935238.

Adapting for the Future

How adaptive optics imaging can help your patients and the future of gene therapy for retinal diseases



By Judy E. Kim, Professor of Ophthalmology, Department of Ophthalmology & Visual Sciences, Medical College of Wisconsin, Milwaukee, WI, USA

Just as we might want to look closer at one star from the night sky, sometimes we want to see individual cells of the retina – and adaptive optics (AO) imaging technology lets us do this. Many of you reading this will be familiar with the concept of AO; it is a technology that improves the performance of optical systems by reducing the effects of wavefront distortions (that mostly come from the lens and the cornea), allowing resolution fine enough to visualize single photoreceptor, retinal blood vessels, or retinal surface. AO has three important components: a wavefront sensor, a controller and a

wavefront corrector, which is usually a deformable mirror that corrects the distortion. The technology can be coupled to available imaging systems, such as fundus cameras or scanning laser ophthalmoscopes (SLO); for example, we are using an AO-confocal SLO system that was built at our institute. But how can AO help patients?

We have been using the technology to study the retina in normal and in disease states. Until recently, only cones could be imaged with AO systems, but scientists at the imaging laboratory of our institute were able to modify the system to show that rods can also be imaged (1). One interesting feature we have seen is that rod and cone reflectance varies over time; the brightness of rods and cones changes throughout the day, almost like they are twinkling (2).

As both rods and cones show similar patterns and durations of “twinkling,” it could be related to circadian rhythm or a metabolic cycle, and we are planning to study this further to elucidate how these changes may indicate photoreceptor function. In retinal diseases, such as cone-rod dystrophy, we have observed bright cones as well as areas of darkness. We have also been studying macular telangiectasia (MacTel), and we also see bright and dark cones. The areas of darkness may indicate absence of cells, while dark cones may indicate abnormal or cones that are not waveguiding. Therefore, the location and the number of dark cones, the extent of dark areas, and the variation of cone density from normal could all be useful biomarkers of disease activity and tracking progression in retinal conditions (3).

I have also found AO useful in examining surgical patients because it can show abnormalities that are not visible with optical coherence tomography (OCT). We have imaged a number of patients following successful surgical closure of macular hole (4). Even though OCT shows excellent anatomic restoration in these eyes, we found significant photoreceptor disruption on AO imaging. We also found that the cone mosaic continues to remodel for over one to two years – which may explain why there can be continued improvement and symptoms of metamorphopsia after surgery in these patients.

Retinal imaging with AO is not limited to the photoreceptors (5). We can go deeper into the eye and see retinal pigment epithelium (RPE) cells and study how disease affects the RPE layer; we can also image the retina superficially at the nerve fiber layer, optic nerve and lamina cribrosa. Due to exquisite resolution, we can image blood flow without the use of a fluorescein dye.

We have found that patients

with significantly advanced retinal disease with decreased numbers of photoreceptors compared to normal retina can still have 20/20 visual acuity. Therefore, there may be a “disconnect” between the anatomy (e.g. cone health and number) and function (e.g. visual acuity) at times. Given that accurate assessment of the type and the extent of diseased photoreceptors might be prerequisite to improving the visual outcome following gene therapy in humans, AO could play an important role in helping identify which patients might be the best candidates for gene therapies. It can be used to monitor non-invasively which patients are anatomically responding to treatment before such information can be obtained by any other method. Therefore, the high image resolution capability of AO to help select ideal candidates may make it an excellent research tool for those who are studying gene therapy.

“AO could play an important role in helping identify which patients might be the best candidates for gene therapies.”

As wonderful as the AO images are, there are currently issues that prevent wide usage in the clinic. While there is a type of AO fundus camera currently

in the market, it is not yet FDA approved. Therefore, in the United States, it is used in a research setting. The type of AO cameras that are being used in the research labs such as ours tend to have higher resolution and can shed more information. However, the imaging time and processing times tend to be quite long at this time. It is hoped that in the future, these deficiencies that prevent use in the clinic can be overcome, allowing the clinicians to be able to fully utilize capabilities of AO imaging.

In summary, functional tests do not tell us everything. AO is a non-invasive imaging technology that can help us detect photoreceptor loss early and may assist us in the future as a biomarker of disease onset and progression. It can help with the selection of ideal candidates for therapies and earlier detection of treatment effect. I believe it will play an important role in the future for assessing the therapeutic potential and outcomes in patients with retinal disorders.

References

1. A Dubra et al., “Noninvasive imaging of the human rod photoreceptor mosaic using a confocal adaptive optics scanning ophthalmoscope”, *Biomed Opt Express*, 1864–1876 (2011). PMID: 21750765.
2. RF Cooper et al., “Spatial and temporal variation of rod photoreceptor reflectance in the human retina”, *Biomed Opt Express*, 2, 2577–2589 (2011). PMID: 21991550.
3. DH Scoles et al., “Non-invasive evaluation of microscopic retinal pathology in macular telangiectasia type 2”, *IOVS*, 55, 5951 (2014).
4. Hansen et al., “Assessing photoreceptor structure after macular hole closure”, *Retina Cases Brief Rep*, 9, 15–20 (2015). PMID: 25525907.
5. DH Scoles et al., “Microscopic inner retinal hyper-reflective phenotypes in retinal and neurologic disease”, *IOVS*, 55, 4015–4029 (2014). PMID: 24894394.

Small Practices Will Survive

Don't believe the hype. The future of ophthalmology practices is not all mergers and acquisitions



By Ravi D. Goel, Regional Eye Associates, Cherry Hill, New Jersey, and Wills Eye Hospital, Philadelphia, PA, USA

Is the future of ophthalmology practices big or small? It's a question being pondered by many – and the common view is that small and solo practices could become a thing of the past. But I want to share my view that small practices will survive, and here's why...

Ophthalmologists are a "savvy" bunch. Back in 1995, during the height of the Clinton healthcare debates and push towards primary care, it was estimated that there would still be sufficient demand for ophthalmologists going forward if our specialty reconfigured as preferred primary eyecare providers (1). In addition, an AOS report published in 2011 described that the ophthalmic community was quick to respond to market demand, and a positive relationship exists between GDP growth and demand for private practice ophthalmologists (2). Interestingly, the AOS study noted a 2–3 year decline in ophthalmologists demand following a recession.

In 2016, David Parke II (Executive Vice President and CEO of the American Academy of Ophthalmology) wrote on the changing eyecare

workforce. He noted that among 17,000 US ophthalmologists (there are 40,000 optometrists), more than 40 percent are 100 percent comprehensive ophthalmologists. He also illuminated that 32 percent are in solo practice and around 60 percent of Academy members are in small groups of 1–3 ophthalmologists (3). So there is this huge cohort of ophthalmologists in small or solo practices who aren't going to disappear overnight.

The bonus is that there will always be enough demand for ophthalmologists. Why? Because approximately 10,000 baby boomers turn 65 every day. And this baby boomer bulge is set to continue for the next 30–50 years (4) – meaning ophthalmologists continue to have the opportunity to thrive in practice. So I am not worried about patient populations. Reimbursements are a different matter – especially since the majority of our patient base consists of Medicare and Medicaid patients, and we face the numerous challenges with acronyms of MIPS, MACRA, PQRS, MU, and perhaps BRCA. But this is where the IRIS Registry is showing itself to be invaluable to our profession.

The IRIS Registry is the nation's first comprehensive eye disease clinical registry. The Registry was launched in recent years and after the government passed legislation to incentivize physician transition towards using electronic medical records (EMRs). IRIS works in the background of EMR systems, extracting data every night from patient visits that day. In a way, the registry has been far more successful than originally anticipated in gathering data and outcomes that are helping patient care. What does this mean for small practices? It helps to relieve the regulatory burden. As the federal government is transitioning to paying doctors for quality rather than quantity, the data collected in the IRIS Registry can show the government that outcome measures are

being met. It relieves a lot of the burden in "paperwork" to reach the incentives and avoid penalties. We are already providing quality care, and the IRIS Registry helps us show that we're meeting measures. Report cards are also issued from the registry to help physician analytics with our patient outcomes. I call it the "small practice savior."

There are a lot of mergers and acquisitions in medicine (think cardiology in the last five years) but ophthalmology may just be unique. I think we've benefitted from technological gains in our profession, including the advent of OCT, increasing efficiencies in cataract surgery, and wonderful treatments for macular degeneration and retinal disease. So we don't necessarily need to merge into big groups. There is, however, a role for ophthalmologists to find their niche – however they like things to be. Ophthalmologists in a big city may be more likely to join a group, but can still thrive in a small practice. Those who are motivated and ambitious – of any age group – can break away and thrive on their own, even if they initially joined a group. Small practice ophthalmologists are not going to wither away: small practices will survive.

References

1. PP Lee et al., "Estimating eye care workforce supply and requirements", *Ophthalmol*, 102, 1964–1971 (1995). PMID: 9098304.
2. RA Adelman and CC Nwanze. "The impact of the economy and recessions on the marketplace demand for ophthalmologists (an American Ophthalmological Society thesis)." *Trans Am Ophthalmol Soc*, 109, 49–65 (2011). PMID: 22253483.
3. DW Parke II. "The changing eye care workforce", *EyeNet Magazine* (2016). Available at: <http://bit.ly/DparkeII>. Accessed July 6, 2017.
4. SL Colby and JM Ortman. "The baby boom cohort in the United States: 2012 to 2060; Population estimates and projections", *Census.gov* (2014). Available at: <http://bit.ly/USboom>. Accessed July 6, 2017.



KEEPING UP WITH PRECISION MEDICINE

HOW WE'RE USING A SPECIALIZED NEXT-GENERATION
SEQUENCING PANEL TO GIVE OCULAR CANCER PATIENTS
ACCESS TO NEW TARGETED THERAPIES

Ruth Steer interviews Rajesh C. Rao

Ophthalmology leads the way when it comes to gene therapy and stem cells. But whilst we may be trailblazing in certain fields, in ocular oncology, we're trailing behind. For the most part, the treatment of ocular and orbital (abbreviated as "ocular") tumors have not yet benefitted from many of the emerging and established technologies in oncology and other disciplines to personalize medicine – and there has been no exploitation of cancer-causing genetic and epigenetic changes for diagnostics and treatment. For instance, some types of breast cancers can be treated by epidermal growth factor receptor (EGFR) inhibitors, and patients with certain lung cancers can receive anaplastic lymphoma kinase (ALK) inhibitors. These therapies

are based on knowing the gene mutations in oncogenes and tumor suppressors, or copy number alterations (too many or too few copies of tumor promoting or protective genes) that drive the growth of the cancer. An emerging field that has deepened our understanding of how tumors form is epigenetics (See "Epigenetics Explained"). In our context, "epigenetics" refers to modifications to DNA or histones that aberrantly switch genes that promote or protect against cancer on or off, without changing the genetic sequence of DNA. No such epigenetic-based therapies currently exist for ocular cancers because epigenetic regulation of ocular cancers remains poorly understood. We're working to help change that. Here's our story so far...

EXPANDING THE HORIZON WITH EPIGENETICS

When we first started paying attention to epigenetics in 2008, the focus was on histone methylation – the addition of methyl groups to histone tails and how that affects gene expression. Though a “hot” area, no one had really examined it in the developing mammalian retina. So we decided to investigate, and published a paper showing how the histone and methyl marks change during retinal development in the mouse (1). We discovered some interesting trends: a lot of these histone marks were upregulated in the inner retina, and some of the enzymes involved were developmentally regulated. One of these, the histone methyl-transferase EZH2, was expressed only during the growth phase of the retina, and then switched off when the retina was formed. Interestingly EZH2 was emerging as a major target for cancer therapies because it appears to be enriched in cells that grow quickly, such as fetal cells as well as cancer cells.

From studying the developing human retinae, we found that EZH2 was highly expressed in fetal retinae, but not postnatally (2). Because embryonic proteins can be expressed in cancer cells (3), we studied retinoblastoma samples, and found that EZH2 was highly expressed in the tumor cells from this childhood cancer. We also found it to be a good biomarker; immunohistochemistry on these tumor samples for EZH2 was almost a black and white indication of where tumor cells are... and where they are not. Histopathologic detection of EZH2 expression allowed identification of single tumor cells that were invading into the optic nerve or adjacent tissues. Because the decision to use systemic chemotherapy is linked to whether retinoblastoma cells have spread to the optic nerve – and beyond – staining these specific markers could help provide better indications of whether further treatment beyond surgery is actually warranted.

EZH2 was already under scrutiny by several companies, and small molecule inhibitors against it were in trials for other tumor types, such as lymphoma. We tested some of those inhibitors and found that they selectively killed the

retinoblastoma cells, sparing the normal retinal cells. This was our entry point and, since then, we’ve published papers showing high levels of EZH2 in different tumors including vitreoretinal and orbital lymphomas, medulloepithelioma, and basal cell skin cancer, which can occur on the eyelid and the orbit, where it is difficult to treat (4–6). Right now, we are looking at some of the pathways downstream of EZH2, including DNA methylation.

A PRECISE APPROACH

An important part of our studies is to help patients with ocular cancers gain access to more targeted treatments. A close

collaborator, Scott Tomlins, helped develop the panel for the National Cancer Institute (NCI) MATCH trial (See “The NCI MATCH Trial”). Together, we’ve been using the same technology to study eye and orbit tumors. But because ocular cancers are quite rare – there are only about five thousand cases per year in the United States (7) – acquiring tissue for study can be challenging. I use the analogy that studying cancer and human tissues is like studying freshwater; just like most freshwater is “locked up” in ice at the poles, most human tissues are embedded in wax and archived in hospitals and medical centers. But this

fixation process and the wax can make downstream research applications more difficult, especially when trying to study the epigenetics. It’s why we’ve had to take a unique approach.

Using a scalpel, we “shave” off sections of samples to collect DNA, which we then put on a next-generation sequencing (NGS) panel (similar to NCI MATCH, see p25) to find mutations, gene alterations or copy number changes in those tumors. The panel is enriched for gene targets for which drugs have already been approved by the FDA (or in trial) for other cancer indications. So far, we’ve discovered many actionable alterations in genes, including *MYD88*, *ARID1A*, *EZH2*, *PTEN*, *TP53*, *HRAS* and *NRAS* (2, 4–6, 8). We’ve also found that eye lymphomas have a certain “flavor” and abundance

“WE HAVE HAD TO DIG
DEEP INTO OUR ARCHIVES
OR COLLABORATE WITH
OTHER CENTERS; IN SOME
CASES WE ARE ANALYZING
SAMPLES THAT ARE 30
YEARS OLD”



Epigenetics Explained




Image credit: The National Cancer Institute.

of mutations that are not present elsewhere; *MYD88* was commonly mutated in orbital marginal zone lymphomas, but uncommonly in marginal zone lymphomas elsewhere in the body (6). As there is already a drug in trial against the mutation we identified, we hope that our orbital lymphoma patients might be attractive candidates.

We're basically looking for the "low hanging fruit" – tumors that haven't yet been sequenced. And with orbit and eye tumors being so much rarer compared with other cancers, we have had to dig deep into our archives or collaborate with other centers to find tumor samples for study; in some cases we are analyzing samples that are 30 years old! But science and sequencing technologies have moved so fast that for relatively

"OUR INITIAL GOAL IS FOR PATIENTS WITH EYE CANCER TO HAVE THE SAME OPTIONS AND TREATMENTS AS PATIENTS WHO HAVE OTHER CANCERS."



The NCI-MATCH Trial

The NCI-MATCH Trial (NCT02465060) is an ongoing precision medicine cancer treatment trial (11). In this study, biopsies from patients are analyzed using an NGS-based panel to identify actionable genomic alterations for precision medicine-based treatment strategies. Patients with advanced solid tumors,

lymphomas, or myeloma who have progressed on standard treatment for their cancer, or patients with a rare cancer for which there is no standard treatment, are eligible for MATCH. Currently, there are 19 treatment arms open to patients, including genetic changes in *EGFR*, *ALK* and *mTOR* (11). In NCI-MATCH “basket trial,” patients can be enrolled in a trial no matter what

kind of cancer they have, provided they have the same mutation that the trial drug is targeting. The trial utilizes the Oncomine Comprehensive Panel (OCP) to detect genomic variants in patient samples (12). The OCP was developed from analysis of over 700,000 tumor samples, and combination of genomic alterations with available therapeutics and ongoing clinical trials.




Figure 1. Workflow of determining driver and potentially actionable genomic alterations in vitreoretinal lymphoma. Adapted from (8).

little money we can use small amounts (as little as 5 ng of tumor DNA) of these archived samples – including those that we thought were “locked up in ice” – and still retrieve usable information. Our initial goal is for patients with eye cancer to have the same options and treatments as patients who have other cancers through basket trials (clinical trials that target cancers based only on whether they contain specific genetic alterations, rather than the part of the body they come from). We hope to exploit drugs in our armamentarium that may be more specific than chemotherapy because they target genetic alterations present in the tumor but not in normal tissue. In the future, we want to help other ophthalmologists and ocular oncologists who see patients diagnosed with eye cancer by using these precision medicine strategies to identify diagnostic

or druggable targets in their patients’ ocular cancers – and thus which clinical trials a patient may be eligible for. And if the drug receives approval, we’ll have made an important link in bridging a drug from other types of cancer or diseases to the field of eye cancer, and help our patients access more targeted therapies.

A CALL FOR COLLABORATION

We’re also hoping to improve diagnosis. Vitreoretinal lymphoma is rare – there are only around 400 cases per year in the US (9). Because of its link to CNS (brain) lymphoma, it’s a deadly disease, with only a quarter of patients surviving more than five years after diagnosis (10). It represents a crucial unmet need, not only because there is no standardized



WHY 'SEXY' NEEDS SUBSTANCE

By Rajesh C. Rao

We all like to hear things in soundbites but, in my view, we should also explain what we mean when we use terms such as epigenetics, stem cells and precision medicine.

I've been in the stem cell field since 1999, and in epigenetics since 2008, and I think the term epigenetics is becoming like 'stem cell' in that it means many different things to different people. Scientists and clinicians have been expressing their concerns about how the term epigenetics can get misused in the media (13) – and we need to be more cautious with it. Why? Epigenetics could essentially mean anything; some of the influences are outside genetics. My concern is that using epigenetics as a 'grab bag' term is not helpful for science, patients or clinicians.


Whenever I talk about epigenetics, I quickly provide context of how I intend to use the term, stating that I am using it to refer to chemical modifications that occur to DNA and histones, and how these changes link to gene expression. Doing so brings me to a relatively focused area, so I can talk about some of the mechanisms driving the changes.

Going back to the stem cell analogy, some clinics state they are using stem cells – but don't truly know if the "stem cells" they purport to use share defining characteristics of these cells such as self-renewal and tissue-specific differentiation (14). And in some cases, these clinics are putting patients in danger; take, for instance, the widely reported case of three female patients in Florida who suffered blindness as a result of an untested "stem cell therapy" (15).

Precision medicine is another grab-bag term. But haven't we always been doing precision medicine? I am a retina specialist, and when I see a patient with macular degeneration or

diabetic retinopathy, I routinely take into account their medical history such as whether they smoke and what medications they take, their A1C, and the findings from the retinal exam. One could (truthfully) say, "I'm practicing precision medicine!" – after all, the treatments are being tailored to the patient based on the unique characteristics of their disease. So again, rather than using 'precision medicine' as a grab bag term, I try to contextualize my usage: "By precision medicine, I mean that the patient has particular germline or somatic genetic changes (mutations or copy number alterations) or epigenetic changes (over expression or under expression of specific genes) – and based on those genetic or epigenetic alterations, I can now link the patient's disease to a more tailored diagnosis, treatment, or experimental intervention being tested in a clinical trial."

The bottom line? The moment we start using specialized terms, such as epigenetics, stem cells and precision medicine, we should also define them and include the context of how we are using them to describe our patients or their treatments.



“OPHTHALMOLOGY CAN
LEARN FROM OTHER FIELDS
THAT ARE LEADING IN
PRECISION MEDICINE, AND
THEN APPLY IT TO
OCULAR ONCOLOGY.”


treatment – but also because it is very difficult to diagnose. In small volume vitreous samples taken from four patients with confirmed or suspected vitreoretinal lymphoma, we identified alterations in *MYD88*, *CDKN2A* and *PTEN*, showing that it is feasible to perform targeted NGS on intraocular liquid biopsies (as small as 500 μ l or 5 ng of DNA) and identify the presence of tumor-causing mutations or copy number alterations (8) (Figure 1 – see p26).

This approach could potentially enhance vitreoretinal lymphoma diagnosis and influence patient care. For instance, prior vitreous biopsies from one of the study cases had all been read as cytologically negative, with neither eye showing the presence of cancer cells. Two years after initial consultation, the patient presented with vision loss and right hemianopia; he had a brain lymphoma mass that was pressing on his visual centers. When we analyzed his original vitreous samples which had been stored in the freezer when collected two years prior to the brain lymphoma, we found tumor DNA confirming what later showed up in the brain: diffuse large B-cell lymphoma. Vitreoretinal lymphoma can be difficult to diagnose through standard cytology approaches, but because our test is so sensitive, as little as 5 or 6 ng of DNA is needed – which can come from just a few tumor cells in the eye. In the near future, we’d like to develop a diagnostic test that can be used by anybody. We already have the basis for the test, but because our research was only based on four samples – about

one percent of all cases in the US – we want to collaborate with others; we need more samples to show that diagnosis using this precision medicine approach could be accurate and beneficial.

MAKING STRIDES FORWARD

The key take home message is this: the technology we need is there, but to make more progress in the field, different teams need to talk. Just as ophthalmology has led the way in stem cells and gene therapy, we can learn from other fields that are leading in precision medicine, and then apply it to ocular oncology. We can use today’s technologies to make powerful advances, to improve both diagnosis and treatment for our patients. Because ocular tumors are so rare, collaboration is really the key – it helps us bring the power of NGS, “big data”



bioinformatics, precision medicine and epigenetic technologies to bear on this intractable problem.

Rajesh C. Rao is vitreoretinal surgeon, clinician-scientist, Assistant Professor of Ophthalmology and Visual Sciences at the Kellogg Eye Center, and Assistant Professor of Pathology, at the University of Michigan, USA. Rao is also the Leslie H. and Abigail S. Wexner Emerging Scholar at the A. Alfred Taubman Medical Research Institute, University of Michigan.

References

1. RC Rao et al., "Dynamic patterns of histone lysine methylation in the developing retina", *Invest Ophthalmol Vis Sci*, 51, 6784–6792 (2010). PMID: 20671280.
2. M Khan et al., "Characterization and pharmacologic targeting of EZH2, a fetal retinal protein and epigenetic regulator, in human retinoblastoma", *Lab Invest*, 95, 1278–1290 (2015). PMID: 26280220.
3. M Monk and C Holding, "Human embryonic genes re-expressed in cancer cells", *Oncogene*, 20, 8085–8091 (2001). PMID: 1178182.
4. RC Rao et al., "EZH2, proliferation rate, and aggressive tumor subtypes in cutaneous basal cell carcinoma", *JAMA Oncol*, 2, 962–963 (2016). PMID: 27054919.
5. SE Avedschmidt et al., "The targetable epigenetic tumor protein EZH2 is enriched in intraocular medulloepithelioma", *Invest Ophthalmol Vis Sci*, 57, 6242–6246 (2016). PMID: 27842164.
6. AK Cani et al., "Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies", *Mod Pathol*, 29, 685–697 (2016). PMID: 27102345.
7. Cancer.org, "What are the key statistics for eye cancer?" (2017). Available at: <http://bit.ly/EyeStats>. Accessed June 13, 2017.
8. AK Cani et al., "Next generation sequencing of vitreoretinal lymphomas from small volume intraocular liquid biopsies: new routes to targeted therapies", *Oncotarget*, 8, 7989–7998 (2017). PMID: 28002793.
9. CC Chan et al., "Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group Symposium", *Oncologist*, 16, 1589–1599 (2011). PMID: 22045784.
10. University of Michigan Research, "Out of sight", (2016). Available at: <http://bit.ly/UMichigan>. Accessed June 13, 2017.
11. National Cancer Institute, "NCI-MATCH Trial (Molecular Analysis for Therapy Choice)", (2015). Available at: <http://bit.ly/MatchTrial>. Accessed June 13, 2017.
12. DH Hovelson et al., "Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors", *Neoplasia*, 17, 385–399 (2015). PMID: 25925381.
13. Chris Woolston, "Researcher under fire for New Yorker epigenetics article", *Nature* (2016). Available at: <http://bit.ly/Woolston>. Accessed July 19, 2017.
14. RC Rao et al., "Stem cells for retinal disease: a perspective on the promise and perils", *Am J Ophthalmol*, 179, 32–38 (2017). PMID: 28428049.
15. E Kuriyan et al., "Vision loss after intravitreal injection of autologous 'stem cells' for AMD", *N Engl J Med*, 376, 1047–1053 (2017). PMID: 28296617.

The Ophthalmologist North America



Building on the success of The Ophthalmologist, our new edition offers the same style of professional, technical and groundbreaking content with a distinctly North American flavor.

Editor of The Ophthalmologist, Mark Hillen, believes the time is right for a dedicated publication.

"Right from the launch of The Ophthalmologist in Europe almost four years ago, we've had calls to bring the magazine to North America. I'm absolutely delighted that we can now give our friends across the Atlantic their own edition."

Publisher, Neil Hanley, says

"It was always our aim to take The Ophthalmologist to the US and Canada. We have taken our cues and influences from some of the most recognizable magazines in the world to create a modern media brand for ophthalmologists, and the whole team are thrilled to properly serve what is perhaps the fastest-paced ophthalmology market in the world."

If you are based in the US or Canada, visit www.theophthalmologist.com to sign up for the print edition of The Ophthalmologist North America.



NextGen

*Research advances
Experimental treatments
Drug/device pipelines*



32–34

First Glimpses of Foveal Function
Raunak Sinha shares how recent research advances are broadening our understanding of foveal function.

35–37

Benchmarking Retinal Detachment
We attempted to understand the field of retinal detachment by performing a benchmarking analysis of the last 5 years of PubMed-listed publications.

First Glimpses of Foveal Function

Can a new understanding of the mechanisms underlying the functional specialization of the fovea change our approach to visual disorders?

By Raunak Sinha

Relative to the rest of the retina, the fovea exhibits striking anatomical and structural specializations that not only support spatial and chromatic sensitivity,

At a Glance

- Foveal signaling and neurophysiological function has long been poorly understood, partly because of long-standing technical challenges; patch clamp electrophysiology and transient gene expression techniques have now permitted the first detailed investigation of how the fovea functions at a cellular and circuit level
- Unexpected findings include the observation that perceptual differences in temporal sensitivity between foveal and peripheral vision originate in the first stage of visual processing i.e. phototransduction in the cone photoreceptors
- Another striking finding is that the responses of the dominant output neurons in the fovea are minimally modulated by synaptic inhibition, unlike most neural circuits
- The study has caused a re-evaluation of foveal function at the cellular and neuronal circuit level and may inform future therapeutic strategies for visual disorders

but also enable maximal visual acuity. So although the fovea subtends only a tiny part of the visual field – about the size of a thumbnail at arm's length – it accounts for approximately half of the information sent to the visual cortex. Given this striking anatomical specialization, should we also expect to find differences between foveal and non-foveal neural cells at the physiological level?

Certainly, the temporal sensitivity – the ability to distinguish changes in visual inputs over time – of foveal circuits is known to be relatively low compared with that of peripheral retinal cells. In fact, foveal temporal sensitivity determines key features of the modern environment, such as celluloid film frame rates and computer monitor refresh rates. Aside from this, we know very little about neural signaling in the fovea; most of our knowledge stems from sparse, decades-old literature. The dearth of data is mainly due to the historical challenges associated with foveal research, not least the technical difficulty of recording intracellular electrical activity in foveal neurons. Moreover, animal models are scarce and expensive, as the fovea is found only in diurnal primates. Only a few labs in the world have worked in this field, and our understanding of neural function in this specialized retinal region remains limited.

New approaches

To me, the sparse literature on foveal function seemed like an incredible opportunity to explore relatively uncharted territory in visual signaling. I had no background in retinal research – but that was something of an advantage, as I wasn't fully aware of the technical challenges that lay ahead! So I joined Fred Rieke's lab at the University of Washington (UW), and began generating patch-clamp recordings from neurons in the fovea. This technique




Figure 1. Patch clamp electrophysiology being performed on foveal neurons.

Credit: Rieke Lab: rieke-server.physiol.washington.edu

(Figure 1) allowed me to measure light-induced electrical responses from single output neurons called ganglion cells. I could measure both the output of the foveal neurons and also the inputs they received from upstream neurons, and compare these measurements with those recorded from their counterparts in the peripheral retina. To complement the electrophysiological results with detailed anatomical investigation, we used gene expression techniques, such as particle-mediated gene transfer – not previously used in primate fovea – in collaboration with Mrinalini Hoon from Rachel

“Our study offers the first glimpse into how the fovea works at a cellular and circuit level and has opened up a whole new research field.”


Wong's laboratory at UW. This allowed transient expression of proteins in various ganglion cells in the fovea.

In essence, my aim was to understand the physiological basis of the differences between foveal and peripheral vision at the level of perception. It wasn't straightforward but it was exciting. Technical challenges included the development of in vitro approaches that minimized foveal damage while permitting reliable measurement of light-evoked responses in the foveal photoreceptors and in the dominant class of output neurons (midget ganglion cells). We were able to measure responses to a visual stimulus from midget ganglion cells within the range of contrast sensitivities previously reported in in vivo recordings. This enabled us to make direct comparisons of the physiological properties of foveal and peripheral retinal neurons. We reported the first intracellular recordings of light-evoked responses from photoreceptors and ganglion cells in the fovea and the first structure-function correlation in the fovea. Patch-clamp electrophysiological methods were crucial for directly measuring excitatory and inhibitory synaptic inputs to foveal ganglion cells and comparing those with ganglion cell outputs (action potentials). When we commenced this research, the published literature showed a complete lack of intracellular recordings from foveal neurons, so it really was uncharted territory – we didn't know what we would find.

New findings

In brief, our work provided the first glimpse into the cellular, synaptic and circuit mechanisms of foveal function, and it turns out to be very different from the operation of non-foveal retina (1).

Firstly, we found that foveal midget ganglion cells expressed fewer inhibitory postsynaptic receptors on their dendrites than their peripheral counterparts. This meant that responses of midget ganglion cells in the fovea are only



Confocal microscope image of rod (green) and cone (red) photoreceptors in a human retina. Image courtesy of NEI/NIH.

minimally shaped by synaptic inhibition – very surprising, because integration of excitatory and inhibitory signals is a key feature of most neural circuits in the brain, including peripheral midget ganglion cells. Indeed, a major research theme has been the extent to which the computational specialization of non-foveal retinal circuits relies on signals from inhibitory retinal neurons (2). For us to show that the responses of foveal ganglion cells are not significantly modulated by either pre- or post-synaptic inhibition, therefore, was most unexpected. Effectively, these cells participate in a neural circuit that operates independently of synaptic inhibition, which is extremely unusual.

Secondly, and contrary to our expectations, we showed that the

different temporal sensitivities of the fovea and peripheral retina did not arise from differences in synaptic inhibition. Rather, they originated in the cone photoreceptors. Foveal cones exhibit response profiles two-fold slower than those in peripheral retina, which is nearly identical to the difference in perceptual sensitivity observed between the foveal and peripheral vision. Thus, lower levels of synaptic inhibition do not seem to be behind the lower temporal sensitivity of the fovea. Instead, it seems that the “frame-rate” capacity of our visual system is set by the very first neurons in the visual pathway.

So, to recap, there were several surprises in this study. We revealed a key difference between foveal and peripheral midget ganglion cells in terms of synaptic




Image of a midget ganglion cell (yellow), the dominant retinal output neuron in the fovea, overlaid on an image of the cone photoreceptor array (magenta) in the fovea. Image courtesy of Mrinalini Hoon

inhibition; the minimal role of synaptic inhibition in the foveal midget ganglion cells was completely unforeseen, given the importance of balanced excitation and inhibition for the operation of most other neural circuits in the brain. Additionally, we found that differences in temporal sensitivity between the two retinal regions may originate in the cones within the phototransduction cascade. The differences provide a simple explanation for the observation that foveal vision is less sensitive to rapidly varying light inputs than peripheral vision, and has significantly changed our understanding of foveal function. Previous models of visual function assumed that differences between foveal and peripheral vision originated in the neural circuits that received input from cone photoreceptors. The heterogeneity of cone responses that we observed means that we must re-evaluate old models – and the conclusions drawn from them.

Our work clearly illustrates that the fovea is not only structurally specialized,

but also employs different computational strategies compared to peripheral retina. This distinction is also important when considering how visual computations are partitioned between the retina and higher visual centers. In sum, our findings have revised our understanding of how the fovea operates at a cellular and circuit level.

New horizons

Our study offers the first glimpse into how the fovea works at a cellular and circuit level and has opened up a whole new research field. The novel application of gene transfer approaches that we've described may permit a wide range of transient genetic manipulations that will allow us to understand the properties of other cell types in the fovea. And that will enable us to fill the void in our knowledge of this crucial component of the human eye. Indeed, given the distinct functional properties of foveal neurons we have revealed, the lack of significant functional data on foveal

circuits, and the implications for the division of computational labor between retina and cortex, our work should be of broad interest to scientists studying visual signal processing. I am certainly pursuing this unique opportunity to unravel the mechanistic basis of other aspects of foveal vision!

The data we present also have implications beyond the theoretical. For conditions involving central vision loss, current therapeutic strategies – including the design of visual prosthetics – are based on studies in peripheral retina, or in retinas from model systems that lack a fovea. The underlying assumption has been that the fovea is a scaled-down version of the peripheral retina, but our study shows that the computational architecture and visual processing mechanisms of the fovea are dramatically different from non-foveal retina. Our new understanding may assist strategies to alleviate important visual deficits, such as macular degeneration.

After a Physiology degree at the University of Calcutta, Raunak Sinha worked at the Tata Institute of Fundamental Research in Mumbai before undertaking his PhD at the International Max Planck Research School in Göttingen, in the Department of Membrane Biophysics at the Max-Planck Institute for Biophysical Chemistry headed by Nobel Laureate Erwin Neher. His doctoral thesis was awarded the Otto Hahn medal. Raunak works in Fred Rieke's laboratory at the Howard Hughes Institute, Seattle, WA.

References

1. R Sinha et al., "Cellular and circuit mechanisms shaping the perceptual properties of the primate fovea", *Cell*, 168, 413–426. PMID: 28129540.
2. RH Masland. "Vision: Two speeds in the retina", *Curr Biol*, 27, R303–305 (2017). PMID: 28441563.2

Benchmarking Retinal Detachment

What does analysis of the last five years of the retinal detachment literature tell us about the priorities of the field and the major contributors to it?

By Mark Hillen

Retinal detachment has many causes, from trauma to pathological myopia to complications arising from cataract surgery. It affects between 0.6–1.8 people

per 10,000 per year (1) – and about three in every thousand people will experience retinal detachment at one point in their life (2). Treatment options vary by the type and location of the detachment, but include cryopexy and laser photocoagulation, scleral buckling, pneumatic retinopexy and pars plana vitrectomy.

However, the field advances; from smaller gauge vitrectomy needles to smarter approaches to scleral buckling. To provide insight into the past and predictions for the future of the field, a series of metrics were applied to the last five years of published literature.

We asked:

- What are the major topics for the field?
- Which publications have the

greatest impact?


- How is the knowledge available online?
- Who are the most prolific authors?


PubMed was searched for “cone dystrophy”, with results limited to the last five years in humans (for a clinical focus). The data were analyzed in Microsoft Excel 2013.

References


1. D Mitry et al., “The epidemiology of rhegmatogenous retinal detachment: geographical variation and clinical associations”, *Br J Ophthalmol*, 94, 678–684 (2010). PMID: 19515646.
2. RF Gariano and CH Kim. “Evaluation and management of suspected retinal detachment”, *Am Fam Physician*, 69, 1691–1698 (2004). PMID: 1508604

Top 20 journals by number of publications






Article Type




Publications per year




Important words


1	Detachment	2,803
2	Rhegmatogenous	477
3	Bevacizumab	155
4	Vitreomacular	115
5	Vitrectomy	990
6	Logmar	203
7	Retinal	2,803
8	Coherence	915
9	OCT	615
10	Macular	943
11	Plana	404
12	Intravitreal	407
13	Vitreoretinal	328
14	23-gauge	76
15	Subretinal	425
16	Acuity	1,418
17	Iris	82
18	Epiretinal	227
19	Vitreoretinopathy	249
20	Tractional	118

Fee or Free?



Language of publications





Making the revolutionary, routine.

ZEISS AngioPlex™ OCT Angiography



A new era in retinal care—right now.

- New vascular information with ultra-clear 3D microvascular visualizations
- Enhanced workflow with non-invasive, dye-free, single-scan angiography
- Advancing OCT with ZEISS' powerhouse CIRRUS™ HD-OCT platform

www.zeiss.com/us/octangio



Profession

*Your career
Your business
Your life*



40-43

Questioning the System
Frederick Fraunfelder and Stevan Whitt discuss physician perplexities on payment for performance programs, highlighting the issues and offering solutions.

44-49

The Extraocular Muscles in ALS: A Research Riddle
Anton Tjust discusses the preservation of eye muscles in ALS, and how the mechanisms behind it could provide a new outlook on this deadly disease.



Questioning the System

A Physician's perspective on perplexing pay for performance programs

By Frederick Fraunfelder and Stevan Whitt

How do physicians feel about compensation being tied to quality of care in medicine? Our guess: disconcerted. Not because physicians don't know how to provide quality care, but because they don't trust how it is measured. Providers across the country are trying their best to keep up with the shifting sands of what is required of them by Medicare, Medicaid, and private insurers regarding how their reimbursement will be connected to quality of care. In hospital-based practices, the hospital CEO may have a plan, and in academic departments, the chair and the Dean may also have a strategy. In this article, we will briefly review the current state of affairs, the possible future, and offer guidance on how best to deal with the uncertainties surrounding the future of compensation models (1–4).

At a Glance

- Changing reimbursement requirements are causing uncertainty and uneasiness – and many doctors mistrust the system
- One key change is the switch from fee for service to quality-based assessments based on patient satisfaction
- In an era of regulatory reform, we overview the current situation and the potential future
- We discuss problems with the system and we offer practical solutions to overcome these uncertainties.



The current situation

Physician compensation in the United States is primarily based on fee for service, but things are changing to connect physician compensation to value (quality + satisfaction/cost). The Affordable Care Act (ACA), and its many amendments, legislates that providers and hospitals must track quality metrics, or be subject to financial penalties that affect physician salaries. From the Centers for Medicare and Medicaid Services (CMS), we started in 2006 with Physician Quality Reporting Initiative (PQRI) and then Physician Quality Reporting System (PQRS), and in 2015 it became Merit-Based Incentive Payment System (MIPS). Now, it will be all rolled up with Alternative Payment Models (APM) under the newest banner, the Medicare Access and CHIP Reauthorization Act (MACRA). Meaningful use basically incentivizes compliance with electronic health record (EHR) keeping and its utilization, and is a quality metric that improves care, but this is not what will be discussed here. Instead, we will focus on what is commonly referred to as non-performance based incentives

(NPIs), using patient satisfaction as our example. Table 1 lists commonly tracked (subjective) variables that could make up NPIs.

A number of companies track and survey every patient seen within a health organization, and provide scorecards so physicians can compare their performance within their institution and nationally with their peers. Organizations also develop or purchase internal systems to track patient satisfaction in real-time. Whilst the intentions of organizations collecting this data are well meaning and worthy of respect, and appear logical and organized, survey strategies vary by methodology (electronic, paper, telephone, cell phone), as well as question content (limiting the number of questions or differences in length and complexity of individual questions). The lack of standardization makes comparing the results of practices around the country suspect. Additionally, physicians are uneasy about tying their salary to quality metrics where there is substantial data subjectivity as well as many sources of potential measurement and reporting



errors. Below, we briefly review some areas of potential error.

1. Not comparing apples to apples

Accumulated data for a given period (sometimes every two months) can be given to a provider in the form of a physician scorecard. The doctor can analyze the accumulated, averaged numeric results or convert this average to a percentile rank for comparison with other physicians and hospital systems. The major error here – especially for ophthalmologists – is that we are a highly subspecialized group and the survey industry has not yet caught up with this concept. Trying to compare the nature of work, or a given survey population, of a uveitis specialist in an academic hospital to a high-volume cataract surgeon in a small town is simply not going to reflect the realities of what is happening with patient care.

“Ophthalmologists are a highly subspecialized group and the survey industry has not yet caught up with this concept.”

2. Patient error

Patients frequently do not answer surveys accurately. In our own experience, there have been many instances of patients mistakenly scoring 1 (lowest ranking on a scale of 1–10) when they meant 10. One result like this, when there may only be 50

Criteria	Score 1–10*
Provider explained things understandably*	
Provider listened carefully*	
Easy to understand information about concerns	
Provider knew medical history	
Provider showed respect for what patient said*	
Provider spent enough time with patient*	
Rating of provider	
Would recommend provider’s office	
Provider Communication Composite (the average of the first three listed: explained, listened, respect, enough time)	

Table 1. Sample Provider Scorecard. *On a scale of 1-10, with 10 being the highest ranking.

patients responding in the tracking period, can be devastating to a physician scorecard and overall percentile rank.

3. Narrow percentile rank window

The range of scores separating top and bottom quartiles is extraordinarily small. For instance, examine the metric of “rate the provider” in a typical patient satisfaction survey; one doctor is rated 10 out of 10 in 78 percent of evaluations, while another doctor in a different part of

the country may score 10s in 80 percent of their evaluations. Converting these average scores to percentile rank, the first doctor is at the 25th percentile and the latter doctor at the 50th percentile nationally. The difference is only 2 percent, but the first physician’s pay is docked because they are below the 30th percentile benchmark. Take this strict benchmark and then consider one of your patients accidentally gave you a 1 out of 10, putting you below the

benchmark, one can then understand the frustration which mounts in the physician community. Additionally, a provider in an upscale low-acuity facility with a relatively affluent patient mix may face different satisfaction challenges compared with a provider practicing with a high acuity case-mix in a very poor, very urban, and culturally diverse setting. How is this comparison fair?

4. *Low number of completed surveys*

Science dictates that we must have a large number of subjects tested to trust a result. If only 10 percent of patients respond to surveys, a selection bias occurs. Those responding may only be the ones who have something to say, and many times, the ones who are vocal have a complaint. It is true that excellent care can lead to positive remarks, nevertheless, how can a physician trust that the respondents represent a real evaluation of their quality of care? Physician scorecards may only have 10 respondents and others may have 200 or more. Comparing groups and penalizing or rewarding compensation on such wide discrepancies will be viewed as unfair unless reliability and accuracy of survey results are well-understood and acceptably valid.

5. *Intra-specialty comparison errors*

A major issue with quality tracking is that some specialties, just by the nature of the practice, will score lower than other specialties. A pain management specialist sees patients in pain all day. A cataract surgeon restores sight all day. Which specialist will score better? Does the cataract surgeon provide higher quality of care just because his scores are higher? Glaucoma management is not a sight restoring practice, it is a sight preserving practice. Neuro-ophthalmology consists of patients with complex diseases that are difficult to understand and live with. How can we compare a neuro-ophthalmologist

or a glaucoma specialist to a LASIK surgeon? Additionally, practices consisting of a majority of long-term patients are very difficult to compare with practices primarily made up of brief episodes of care commonly found in specialty care. Is the satisfaction of a patient similar between these two settings? These questions are rhetorical as there don't appear to be any fair answers at this time.

*“How can we
compare a neuro-
ophthalmologist
or a glaucoma
specialist to a
LASIK surgeon?”*

6. *Government*

The government keeps moving the needle and changing its requirements. The fact that the ACA created PQRI, then PQRS, and then MIPS should tell you that we cannot predict the future. Will Obamacare be repealed or will it evolve and change? This uncertainty leads to uneasiness in the physician community. What does appear certain, however, is that quality will count. How much it counts and how accurately and fairly the government applies financial penalties for non-compliance are the real questions.

Dealing with Uncertainties

Here, we present some solutions to the imperfections that are discussed above:

1. *Intrinsic motivation*

Doctors want to provide quality care;

however, financial incentives and penalties may be creating perverse effects on quality. If doctors prioritize pleasing patients, inappropriate prescriptions and reluctance to deliver truthful or bad news may be the result. Obviously, this isn't how we practice but there is a sliver of truth to this concept. Recent articles have suggested that our innate desire to work, and the satisfaction we derive from quality work is as important to an individual as hunger or thirst (1). The future of quality care must focus on this intrinsic motivation that physicians possess. After all, for most of us, the drive to relieve pain and suffering is the main reason we became doctors in the first place.

2. *Compare similar organizations*

We must compare similar practice settings, such as academic institutions to other academic institutions, and private practices to other private practices, from similar parts of the country. Data needs to reflect that a glaucoma surgeon in an academic department in Philadelphia is not the same as a private practitioner in mid-Missouri. The good news is organizations that track quality data are becoming more sophisticated over time and intra-specialty comparisons should become more accurate in the future.

3. *Improve infrastructure and increase support staff*

There are two key elements we believe will improve patient satisfaction, and hence improve quality of care, scores: improving infrastructure and supplying ample support staff. Well-staffed, clean, and modern facilities provide patients a concierge experience, similar to what might be found in a nice restaurant with valet parking or flying business class on an airline. Older, understaffed clinics could have a major impact on the overall “rate the provider” and/or “communication” scores. If an organization is having difficulty



"There are many solutions to the problems we face."

improving quality scores and many of the metrics have been extensively addressed over the preceding months/years, focusing on infrastructure and staffing seem likely to have a significant positive impact. The entire patient experience surrounding a health care visit reflects upon the physician regardless of the one-on-one interaction between patient and doctor.

4. *Thresholds for success*

The benchmarks for success are many times set by the organization. Setting the benchmark at the 30th percentile could enable physicians to improve over time. If the benchmark is at the 50th percentile, and historically the organization has been at the 17th percentile for years, there could be morale problems and loss of physician engagement without a celebration of the incremental successes. The hill may be simply too steep to climb if rate of change is unrealistic. Early on, set achievable goals and then move the goals to more ambitious levels as survey or other results improve.

Concluding thoughts

The goal of physicians and hospitals is to provide the highest quality of care possible. The system is fraught with complexity and errors well known to physicians, and therefore many doctors do not trust the system to fairly apply quality metrics that affect physician compensation. Still, there are many solutions to the problems we face. The keys are to have patience, and to apply a multi-faceted approach to quality

improvements. It is important to improve subjective survey methodologies while also improving the whole patient care experience, which must include adequate infrastructure and a fully staffed clinic. If we, as a healthcare community, can accomplish some of these goals, then doctors will be able to trust "the system" and patients will get the quality care that they deserve.


Frederick Fraunfelder is Chairman and Roy E. Mason and Elizabeth Patee Mason Distinguished Professor at the University of Missouri, Department of Ophthalmology.

Stevan Whitt is Senior Associated Dean for Clinical Affairs at the University of

Missouri School of Medicine and Chief Medical Officer for MU Health Care.

References

1. DH Pink. "Drive: The surprising truth about what motivates us." Riverhead Books, New York, NY: 2009.
2. AT Chien et al., "Physician financial incentives and care for the underserved in the United States", *Am J Manag Care*, 20, 121-129 (2014). PMID: 24738530.
3. ME Porter. "What is value in health care?", *N Engl J Med*, 363, 2477-2481 (2010). PMID: 21142528.
4. TH Lee, A Bothe, GD Steeler. "How Geisinger structures its physicians' compensation to support improvements in quality, efficiency, and volume", *Health Aff*, 31, 2068-2073. PMID: 22949457.



The Extraocular Muscles in ALS: A Research Riddle

Could the preservation of the eye muscles in ALS provide a new outlook on a deadly disease?

By Anton Tjust

Amyotrophic lateral sclerosis (ALS) is a devastating condition. An incurable neurodegenerative disease, it is characterized by a progressive loss of upper and lower motor neurons, leading to complete paralysis and eventually death through respiratory failure, usually within three to five years of symptom onset. Currently, the only treatment available is riluzole, but this drug only extends the lifespan of ALS patients by an average of two to three months.

Clinically, the disease can present itself with intriguing variability. It may manifest at any age, but often occurs in people who are middle-aged or older. Subsequent survival is also variable, with some patients surviving under a year, and a small proportion living for decades. When the patient experiences the first symptoms, they are mostly restricted to a single extremity – for example, the right hand. The disease most commonly presents itself distally with a mixture of upper and lower motor symptoms, such as weakness and loss of dexterity. This is later followed by a progression into more proximal muscles, appearance of the same symptoms in the ipsilateral leg, and eventually, involvement of all voluntary muscles in the body. In about 25 percent of the cases, the disease manifests in the bulbar region, first affecting muscles of articulation and mastication. Another variable trait in ALS is the degree of

cognitive involvement. Some patients retain all of their premorbid personality and functions, and some patients develop an outright frontotemporal lobe dementia.

ALS and the eye

Despite the various ways in which ALS can present itself, nearly all ALS patients have one thing in common: you don't encounter them in the ophthalmologist's office. With some notable exceptions (1), the extraocular muscles are seemingly preserved in most ALS patients, even until the terminal stage. Notably, eye movements and blinking are usually the last modes of communication available to terminal ALS patients (2). But why?

“Nearly all ALS patients have one thing in common: you don't encounter them in the ophthalmologist's office.”

That simple question presents an area of study with huge potential; understanding the underlying mechanisms for eye motility sparing in ALS could provide new insights into how the progress of ALS could be slowed down in more vulnerable muscles.

From an evolutionary perspective, extraocular muscles and their motor neurons are ancient companions that pre-date the advent of terrestrial life on Earth. Extraocular muscles are

present and innervated according to a principally similar system in lampreys, whose ancestors (Cambrian cyclostomes) diverted from what would evolve into jawed fish (gnathostomata) between 460 and 535 million years ago. This implies that extraocular muscles are at least that old. The muscles of the trunk, gills and fins of Cambrian fish have since evolved into muscles of terrestrial locomotion, anti-gravity balance, breathing and grasping, but the extraocular muscles still serve (though with greater performance) the same basic function of orienting the gaze, just as they did half a billion years ago.

Exploring the mysteries of eye motility In my recent doctoral thesis, I explored the sparing of eye motility, using histological studies of the extraocular muscles of ALS patients and the most commonly used mouse model for ALS. Although ALS is a motor neuron disease and therefore frequently studied from the perspective of the central nervous system, skeletal muscles are also important players in its progression. During embryonic development and after the initial establishment of the neuromuscular junction – the specialized synapse that forms between muscle fibers and motor neuron axons – muscle fibers provide the innervating motor neuron with neurotrophic factors, such as glial cell-derived neurotrophic factor (GDNF). The neurotrophic factors are retrogradely transported along the axon back to the nerve cell body in the central nervous system, promoting neuronal survival signaling. The relationship between muscle fibers and motor neurons is critical during embryonic development, where 30–50 percent of all motor neurons projecting to muscles in the limbs and trunk are lost to apoptosis in favor of those motor neurons that are more successful in establishing contact with many muscle fibers. In contrast,



Asking the Right Questions

The relative resistance of extraocular muscles in the context of ALS, when viewed on its own, seems like a pathophysiological oddity. But if we take a broader view of the numerous degenerative diseases being studied across different areas of medical research, a very different picture emerges.

In different neurodegenerative diseases, monogenetic, dominantly inherited sub-forms of diseases have been identified, where a seemingly ubiquitous (or near-ubiquitous) gene product mysteriously exerts its pathogenic effect mainly on a specific type of cell. For example, whereas hexokinase 1, an enzyme responsible for the phosphorylation of glucose, is present in most tissues in the body, specific mutations in the gene that codes for it can lead either to a dominantly inherited retinitis pigmentosa or, in the case of another missense mutation, a recessive form of Charcot-Marie-Tooth disease. Mutations in the gene coding for superoxide dismutase 1 are responsible for approximately six percent of ALS cases. But despite the pancellular ubiquitous nature

of this enzyme (with the highest concentrations actually found in the liver), the mutated form of the protein seems to primarily affect motor neurons in the CNS.

Again, in retinal disease, mutations in the gene coding for bestrophin-1 leads to vitelliform macular dystrophy, a progressive retinal disease that mostly spares the rods. Interestingly, bestrophin-1 seems to be important in chloride ion shuttling in different types of epithelia throughout the body (such as in the airways and colon), not just in the retina. Apparently, in the complex constellation of genes and proteins that sustain our cells, certain cellular processes have become more robust and tolerant to flaws in some cell types than in others.

It is reasonable to look at any disease based on how the patient presents him or herself and ask yourself: “What is wrong with organ X in patient Y?” However, as researchers and physicians, we are looking for solutions to problems. Sometimes we should look for answers from the other end of the tube and ask ourselves, “If this cellular problem is so ubiquitous in my patient, what are cells X and Y doing right that cell Z is doing wrong?”

muscle fibers in the extraocular muscles appear to provide maturing motor neurons with more generous amounts of neurotrophic factors, and therefore a much larger proportion of motor neurons escape apoptosis – a fact that also explains the exceptionally small motor unit sizes (the relationship between the number of muscle fibers controlled by a single neuron) present in the extraocular muscles.

Studies have shown that deterioration of the contact between muscle fibers and

motor neurons, starting at the so-called neuromuscular junction, is an early manifestation of ALS that precedes the actual loss of motor neurons. Therefore, adaptations and maladaptations that take place at the level of the neuromuscular junction could play a large role in the progression of ALS. A good example of this is the observation that when GDNF is overexpressed in the muscles of ALS animal models, it leads to a prolonged survival of the animals, whereas overexpression in glial cells located

much closer to the motor neurons in the spinal cord has no such effect. Further examples of this relationship between muscle fibers and motor neurons are conditional knockout mice where ablation of satellite cells, resident stem cells of muscle tissue, leads to impairment in the re-establishment of neuromuscular junction following nerve injury (3).

“We asked ourselves – what role might satellite cells play in the resilience of extraocular muscles?”

Satellite studies

Satellite cells are present in all muscles of the body, and are normally in a resting state. In response to training or injury, they can become activated, causing them to proliferate and generate new myonuclei for growing and regenerating muscle fibers. Satellite cells in extraocular muscles differ from other satellite cells in several regards. Compared with other satellite cells, they maintain a heightened expression of several developmental transcription factors and have been shown to proliferate and produce new myonuclei more efficiently than limb muscle satellite cells when engrafted into muscle tissue. It has also been proposed that they are more abundant, and in a more continuous state of activation, when compared with satellite cells in

limb muscles (4). Interestingly, in vitro studies involving satellite cells from limb muscle biopsies of ALS patients and satellite cells from the most commonly used mouse model for ALS have shown that their growth performance in vitro is impaired compared to satellite cells derived from unaffected patients. Could satellite cells in limb muscles become worn out in a protracted disease course?

In our research group, we asked ourselves – what role might satellite cells play in the resilience of extraocular muscles to ALS? Our results (both published and as of yet unpublished) (5, 6) suggest that the previously reported abundance and continuous activation of satellite cells in extraocular muscles might have been overstated, and that only a small portion of the extraocular muscle, close to the tendon, maintains an increased pool of satellite cells. We found that the majority of the muscle belly contains generally low numbers of satellite cells, and the majority of them are not in an active state. Further analysis of extraocular muscles from ALS patients typically varied between normal and high levels compared with normal elderly sedentary individuals and did not appear to wear out or decrease in numbers during a protracted disease course (Figure 1). Rather, those muscle fibers in the most severely affected limbs that still retained contact with a motor neuron tended to increase in size together with an increase in the number of satellite cells and myonuclei associated with them. Therefore, it seems that satellite cells, while possibly affected at a level that can be demonstrated in culture conditions, are able to perform well enough in their native niche




Figure 1. Fluorescence images of neuromuscular synapses, in one extraocular muscle (left column) and one limb muscle (right column) in an ALS mouse model. The contact between motor axon (green) and motor endplate (red) is retained in extraocular muscles (bottom left), whereas the contact is broken and disappears in limb muscles as the disease progresses (bottom right).





Figure 2. Fluorescence images of a cross-sectioned extraocular muscle (left column) and a cross-sectioned limb muscle (right column) from an ALS patient. Satellite cells (white arrows) and other myogenic stem cells (white arrowheads), are identified by their molecular markers Pax7 (red) and NCAM (yellow) and presented in relation to cellular membranes (grey – top row) and to cell nuclei (blue – bottom row). It seems that satellite cells are still present in both extraocular muscles and limb muscles at the very terminal stage of the disease.




“We believe that eye motility is maintained because of compensatory mechanisms elicited by specific fiber types.”

within the muscle. By extension, the distinguishing traits of satellite cells in extraocular muscles does not appear to be a key element in the sparing of eye motility in ALS.

Making connections

In both the animal model (Figure 2) and in ALS patients, there is a maintained presence of terminal axons at the muscle fiber endplate, in contrast to limb muscles, where large portions of the muscle fibers lose axonal contact (7, 8). Loss of axonal contact is an early manifestation of ALS, which suggests that the protective mechanisms present in the extraocular muscles are influencing disease progression at a relatively early stage. However, my preliminary, unpublished data suggest that not all fiber types in the extraocular muscles are preserved. Slow-type muscle fibers, which in the extraocular muscles are innervated at several points along the length of the fiber rather than at a single point in the middle (as is usual for muscle fibers) appear to be affected by ALS, decreasing in size and proportion in terminal patients. We believe that eye motility is maintained not because of a general sparing of all fiber types in the extraocular muscles, but rather because






Figure 3. Comparison of motor axons (red) forming synapses with the motor endplate (blue) in limb muscles from two SOD1 ALS mice that were injected after symptom onset with either an empty AAV9-vector (left panel) or an IGF-2-expressing AAV9-vector (middle panel), showing how IGF-2, a growth hormone normally more highly expressed in oculomotor neurons than in spinal cord motor neurons, improves the sprouting capacity of the remaining motor neurons. Mice treated with this vector also exhibit a slower progression rate and survive longer than mice that were treated with the sham vector (right panel). Adapted from (10).

of compensatory mechanisms elicited by one or several other of the specific fiber types present in the extraocular muscles.

A powerful tool

Other investigators have tried to answer the question of differential vulnerability in ALS by comparing the transcriptomes of vulnerable motor neurons with spared motor neurons. One such study (9) has revealed that oculomotor neurons natively express higher levels of several growth factors. And the factor IGF-II seems to exert a neuroprotective effect on spinal cord motor neurons cultured in vitro, and when overexpressed through an injected viral vector (Figure 3), extends the lifespan of the most commonly used ALS mouse model by around 10 percent (10). Also, besides the presence of neurotrophic factors and other growth factors, the intense activity in oculomotor neurons has also lead to numerous evolutionary adaptations to sustain the constant activity and stresses of ion cycling that takes place with each depolarization cycle. Such adaptations

include a different composition of GABA-receptors with more powerful inhibitory responses, as well as a lessened susceptibility to glutamate excitotoxicity, a mechanism that has been recognized as an important contributor to ALS pathophysiology since the early 1990s.

Future studies will hopefully answer the question of whether the sparing of eye motility in ALS is a result of the summation of many factors that happen to be beneficial in delaying the deleterious processes of ALS, or whether more specific traits present in the oculomotor neurons have the coincidental effect of delaying ALS. Nevertheless, studying selective sparing is a powerful tool for researchers in different fields, as it encourages us to learn from biological systems that already, through pre-existing tools, have a solution to the problems we face.

Anton Tjust is a Researching Physician at the Department of Pharmacology and Clinical Neuroscience, Umeå University, and an intern at the University Hospital of Umeå, Sweden.

The author reports no conflicts of interest relevant to the content of this article.

References

1. H Hayashi, S Kato, "Total manifestations of amyotrophic lateral sclerosis. ALS in the totally locked-in state", *J Neurol Sci*, 93, 19–35(1989). PMID: 2809628.
2. AR Murguialday AR, et al., "Transition from the locked in to the completely locked-in state: a physiological analysis", *Clin Neurophysiol*, 122, 925–933 (2011). PMID: 20888292.
3. W Liu et al., "Inducible depletion of adult skeletal muscle stem cells impairs the regeneration of neuromuscular junctions", *eLife*, 4, (2015). PMID: 26312504.
4. KM Kallestad et al., "Sparing of extraocular muscle in aging and muscular dystrophies: a myogenic precursor cell hypothesis", *Exp Cell Res*, 317, 873–885, (2011). PMID: 21277300.
5. M Lindstrom et al., "Pax7-positive cells/satellite cells in human extraocular muscles", *Invest Ophthalmol Vis Sci*, 56, 6132–6143 (2015). PMID: 26393672.
6. AE Tjust, "Extraocular muscles in amyotrophic lateral sclerosis [Summary]", *Umeå University* (2017). Available at: bit.ly/tjust-thesis. Last accessed April 25, 2017.
7. AE Tjust et al., "Unaffected motor endplate occupancy in eye muscles of ALS G93A mouse model", *Front Biosci (Schol Ed)*, 4, 1547–1555 (2012). PMID: 22652891.
8. JX Liu et al., "Distinct changes in synaptic protein composition at neuromuscular junctions of extraocular muscles versus limb muscles of ALS donors", *PLoS One*, 8, e57473 (2013). PMID: 23468993.
9. E Hedlund et al., "Global gene expression profiling of somatic motor neuron populations with different vulnerability identify molecules and pathways of degeneration and protection", *Brain*, 133, 2313–2330 (2010). PMID: 20826431.
10. I Allodi et al., "Differential neuronal vulnerability identifies IGF-2 as a protective factor in ALS", *Sci Rep*, 6, 25960 (2016). PMID: 27180807.



Providing For All

Sitting Down With...
Gullapalli Rao, Founder and
Chair of the L V Prasad Eye
Institute, Hyderabad, India

Congratulations on your induction into the ASCRS Hall of Fame!

I feel very humbled and honored. To be commemorated in this way is a huge deal and totally unexpected. When I accepted the honor, I told the audience that the very fact they had recognized me was symbolic of their commitment to eliminate needless blindness in the world.

You were a former IAPB president, and your career has focused heavily on providing universal eyecare...

I am passionate about it. When we launched the Vision 2020 program nearly 20 years ago, one of our friends said, "There may be disputes about human rights, but there should be no dispute about the human right to sight." And I strongly feel that way too – everybody should have the right to good health and education. I feel very happy that the IAPB has been successfully tackling these issues – and putting blindness on governmental agendas.

As I understand it, there is no parallel in any other area of healthcare. We have everyone involved; both governmental and non-governmental sectors have come together to eliminate one of the major public health problems in the world. And through Vision 2020 and the other efforts of many organizations around the world, the resources available to eyecare have become much larger. By 2020, a larger number of countries will have the necessary framework to deliver high-quality care. I think that preventable problems like river blindness, trachoma and vitamin A deficiency will be more or less eliminated by 2025. We're already testing cost-effective solutions for cataract and refractive errors, and next I think public health approaches will tackle the major impending problems (like diabetic retinopathy and glaucoma) head on.

What influences your values?

The way I was brought up strongly influenced me – starting with my

grandfather who was a freedom fighter, to my father who came from a very humble background but became an ophthalmologist. He always told us that education is the most important thing in life – but that there is no need to show off. My parents are very simple people and that has hugely influenced who I am today – it all sunk in to become part of my personality. I have also had great and inspiring teachers, from those at the village school I went to in my early childhood to some of the most outstanding leaders in the field of eyecare.

"Everybody should have the right to good health and education."

How did you embody your beliefs at your institute?

Thirty years ago, when I came back to India from the US, my vision was to develop a high-quality academic eye center in Hyderabad – and nothing beyond that. But as the work began, we started seeing the problems – and their magnitude and variety. We saw that the real problems were out in remote and rural communities – and that led to a steady evolution of the institute based on real need and how best we could take care of the most disadvantaged populations. And our work will continue. One of the unique features of our institute is the interesting blend of cutting-edge research, care and education, alongside the horizontal approach of going to the remotest rural and tribal areas to take care of the people who need our services the most.

What is your current involvement in the institute?

Since I stopped delivering patient care 15 years ago, I have been mostly involved in looking at the future of the institute; the vision, new partnerships and collaborations and networking across the world, as well as raising and mobilizing more resources for our work.

I think I have the best job in ophthalmology in the world! I have a combination of everything ophthalmology has to offer – leadership, institute development, executive responsibilities, patient care and policies, education, research and innovation. I have been very fortunate to experience every aspect of ophthalmology and eyecare. But one thing I have not done is work for an ophthalmic investor!

What comes to mind when you reflect on your career?

There are three defining aspects of my professional career; the first was growing up in a village until I was 10 years old, which laid a very strong foundation for my life and values, as I noted above. The second big event was my residency training in New Delhi, where my thinking changed from the concept of simply practicing medicine to combining it with teaching and research. And thirdly, I was greatly inspired and influenced by those who taught me at US institutions. However, my career would not have been possible without the support of my family and my wife – who has always been behind me. Nor would it have been possible without the many dedicated and hard working associates at L V Prasad who derive such pleasure from touching some of the most neglected people in the world. All of these things contributed to where I am today, and I am so grateful to everyone.

Any advice for those following in your footsteps?

Just to do your thing and chase your dreams – and the rest will follow.

Working together. Naturally.



A restorative approach to IOP control.

SLT and ABiC™ work to control IOP by a process of restoration of the natural outflow pathways. This is in contrast to traditional glaucoma surgeries and other MIGS procedures, which attempt to mechanically change or bypass the pathway of aqueous outflow.

SLT stimulates a process of cellular regeneration to create a healthier, more porous TM structure. On average, SLT achieves a 30% reduction in IOP when used as a first-line therapy.

ABiC™ is a new ab-interno MIGS procedure that flushes out the natural outflow channels, without damaging tissue, to achieve an average IOP reduction of 30%*.

Contact us on 855-767-5784 to learn more about the new Tango Reflex™ SLT/LFR/YAG laser.



LEARN MORE AT WWW.ELLEX.COM/SLT-ABIC-NATURAL-PARTNERSHIP

*E&OE. © 2017 Ellex Medical. * 228-eye ABiC 12-Month Case Series Data, presented at ASCRS 2016. Data on file. Ellex Medical.

